SG Americas Securities LLC Acquires 10,800 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

SG Americas Securities LLC increased its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 28.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 48,550 shares of the company’s stock after purchasing an additional 10,800 shares during the period. SG Americas Securities LLC’s holdings in MaxCyte were worth $228,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the business. Willis Investment Counsel bought a new stake in MaxCyte in the 4th quarter worth about $2,585,000. Vanguard Group Inc. increased its holdings in MaxCyte by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 5,038,847 shares of the company’s stock worth $15,721,000 after buying an additional 67,917 shares in the last quarter. Deutsche Bank AG increased its holdings in MaxCyte by 22.8% in the 3rd quarter. Deutsche Bank AG now owns 37,294 shares of the company’s stock worth $116,000 after buying an additional 6,915 shares in the last quarter. Legal & General Group Plc grew its stake in shares of MaxCyte by 23.9% during the 3rd quarter. Legal & General Group Plc now owns 74,104 shares of the company’s stock valued at $231,000 after purchasing an additional 14,288 shares during the period. Finally, Alberta Investment Management Corp grew its stake in shares of MaxCyte by 13.0% during the 3rd quarter. Alberta Investment Management Corp now owns 199,823 shares of the company’s stock valued at $623,000 after purchasing an additional 23,011 shares during the period. 68.81% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Stephens restated an “overweight” rating and set a $11.00 price target on shares of MaxCyte in a research note on Wednesday, March 13th. BTIG Research cut their price target on MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Finally, William Blair reiterated an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th.

Insider Buying and Selling

In other news, Director John Joseph Johnston sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $5.12, for a total transaction of $25,600.00. Following the sale, the director now directly owns 120,583 shares of the company’s stock, valued at approximately $617,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.00% of the stock is owned by insiders.

MaxCyte Trading Up 1.0 %

NASDAQ MXCT opened at $4.13 on Friday. The stock’s 50 day moving average is $4.43 and its 200 day moving average is $4.25. MaxCyte, Inc. has a 12 month low of $2.45 and a 12 month high of $5.55. The stock has a market cap of $431.17 million, a PE ratio of -11.16 and a beta of 1.34.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%. The company had revenue of $15.67 million for the quarter, compared to analysts’ expectations of $15.60 million. On average, analysts forecast that MaxCyte, Inc. will post -0.53 EPS for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.